Spanish actor Antonio Banderas has pledged financial support to renowned biochemist Dr. Mariano Barbacid’s research aimed at finding a cure for pancreatic cancer, one of the deadliest cancer types. Banderas announced his commitment via social media, expressing hope that his donation will hasten the development of treatments that could greatly improve patient survival.
Banderas, who manages the philanthropic foundation Lágrimas y Favores, emphasized that in an era marked by widespread conflict and disillusionment, researchers like Barbacid serve as a beacon of hope. Through his foundation, he will direct funds to support Barbacid’s team as they advance their investigations into this devastating illness.
Challenges in Pancreatic Cancer Research
Pancreatic cancer is notorious for its aggressive behavior and grim prognosis, with most diagnoses occurring at late stages when curative options are limited. The five-year survival rate remains under 10 percent globally. Its marked resistance to standard therapies has made pancreatic cancer a critical focus in oncology research worldwide.
Dr. Mariano Barbacid, a leading Spanish cancer scientist, has dedicated decades to uncovering the molecular causes of this disease. He leads the Experimental Oncology Group at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid. Barbacid’s groundbreaking work on oncogenes—genes that can trigger cancer when mutated—has significantly shaped scientific understanding of tumour development.
Recent Scientific Breakthroughs in Treatment
Barbacid’s research team recently achieved a major milestone by eliminating pancreatic tumors in mice through a novel drug combination, marking a first in preclinical studies for this cancer type. Published in the Proceedings of the National Academy of Sciences, the study showcased a triple therapy that simultaneously targets three critical molecular pathways involved in tumor growth.
This approach focuses on the KRAS oncogene, mutated in over 90 percent of pancreatic cancers, alongside proteins that contribute to tumor persistence and treatment resistance. After application of the therapy, treated mice remained cancer-free for extended periods without notable side effects, suggesting promising potential for this strategy.
Despite this success, experts caution that translating these findings from animal models to human patients will require further development. Barbacid has stated that adapting the therapy for human clinical trials will take additional efforts and significant funding, with clinical testing likely years away.
Profile of a Leading Cancer Researcher
Dr. Mariano Barbacid’s career spans more than four decades in cancer biology. He completed his Ph.D. at Universidad Complutense de Madrid in 1974 and trained at the US National Cancer Institute before forming his own research group. His early discoveries include isolating the first human oncogene and identifying cancer-associated mutations, foundational achievements in tumour biology.
Barbacid also contributed to advanced cancer therapies by identifying important molecular targets such as the TRK oncogene. In the late 1990s, he served as Vice President of Oncology Drug Discovery at Bristol-Myers Squibb, where he played a key role in pioneering precision medicine approaches.
Returning to Spain in 1998, Barbacid founded the CNIO, which quickly gained a reputation as a world-class centre for cancer research. Though he resigned as director in 2011 to concentrate on hands-on research, he remains a leading figure in the oncology field. His work has been recognized internationally, including membership in the US National Academy of Sciences and fellowship in the American Association for Cancer Research.
Progressing Toward Clinical Application With Funding
The encouraging results from preclinical trials have fueled renewed efforts to advance Barbacid’s therapy toward treatments for patients. An online fundraising initiative by the Fundación CRIS Contra el Cáncer swiftly exceeded its target, raising over €3.5 million to support subsequent phases of the research.
Yet, additional investment is critical to bridge the gap to human clinical trials. Barbacid estimates that approximately €30 million will be required to complete the preparation stages, including therapy optimization and safety evaluations, before early human testing can begin.
Broad Support From Public and Scientific Communities
Barbacid’s work has garnered significant attention both in Spain and internationally. More than 80,000 people have signed a petition advocating for him to receive the Nobel Prize in Medicine, reflecting widespread public recognition of his contributions and hope for the impact of his research.
Scientists underline that while the animal model results are unprecedented, transferring these breakthroughs to effective human therapies involves many complexities. The combined support from the public, scientific community, and influential individuals such as Antonio Banderas highlights the collaborative effort necessary to achieve this goal.
“In a world marked by violence, confusion, disenchantment and stupidity, scientists like Barbacid represent a beacon of hope.” – Antonio Banderas, Actor and Philanthropist
A Critical Moment in the Fight Against Pancreatic Cancer
With backing from the scientific field, philanthropic groups, and now high-profile supporters, Barbacid’s research is at a pivotal stage. The financial commitment from Antonio Banderas’s foundation is expected to help maintain momentum, bringing scientists closer to turning laboratory discoveries into viable therapies that could dramatically improve survival rates for pancreatic cancer patients.
